SCOPE Analytic Treatment Interruption Protocol — SCOPE-ATI  

HIV/AIDS Clinical Trial

Official title: Analytic Treatment Interruption in HIV Infection

Status Recruiting

Clinical Trial Summary

The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time.

Clinical Trial Description

In this study, people living with HIV will undergo intensive sampling prior to and following an interruption of their antiretroviral therapy (ART). Individuals will be asked to resume ART once the virus is detectable, or after approximately three weeks if the virus remains undetectable.

Individuals who were able to control their virus before ART ("controllers") will be able to participate in an extended treatment interruption and have less restrictive ART restart criteria.

The overall goal of the study is to characterize the interaction between the host and the virus at the earliest stages of virus replication and to identify predictors of rebound before virus becomes detectable. ;

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• HIV/AIDS

• NCT number: NCT04359186
• Study type: Interventional
• Source: University of California, San Francisco
• Contact: Steven Deeks, MD
• Phone: 415-476-4082
• Email: steven.deeks@ucsf.edu
• Status: Recruiting
• Phase: N/A
• Start date: October 15, 2020
• Completion date: June 2026